RecruitingPhase 3NCT05797610
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
Studying IgA Nephropathy
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Hoffmann-La Roche
- Principal Investigator
- Clinical TrialsHoffmann-La Roche
- Intervention
- Sefaxersen (RO7434656)(drug)
- Enrollment
- 428 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (20)
- Alabama Kidney Research - ERN - PPDS, Alabaster, Alabama, United States
- UAB Nephrology Research Clinic, Birmingham, Alabama, United States
- Sunrise Medical Management LLC, Surprise, Arizona, United States
- Tucson Neuroscience Research - M3 WR, Tucson, Arizona, United States
- Kidney Disease Medical Group Inc-1505 Wilson Ter, Glendale, California, United States
- Southern California Medical Research Center, La Palma, California, United States
- Academic Medical Research Institute - Los Angeles, Los Angeles, California, United States
- University of California, Los Angeles (UCLA) - Hematology/Oncology Santa Monica, Los Angeles, California, United States
- Los Angeles County Nephrology, Montebello, California, United States
- North America Research Institute-San Dimas, San Dimas, California, United States
- Hope Clinic & Research Center, Hialeah, Florida, United States
- LCC Medical Research - Miami - ClinEdge - PPDS, Miami, Florida, United States
- Central Florida Kidney Specialists, Orlando, Florida, United States
- L&C Professional Medical Research Institute, West Miami, Florida, United States
- Cowry Medical Group LLC, Acworth, Georgia, United States
- +5 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05797610 on ClinicalTrials.govOther trials for IgA Nephropathy
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07182227PS-002 for the Treatment of IgA Nephropathy in AdultsPurespring Therapeutics Limited
- RECRUITINGPHASE3NCT07390123Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANHaisco Pharmaceutical Group Co., Ltd.
- RECRUITINGPHASE3NCT06994845Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Iptacopan in Pediatric Patients With Primary IgANNovartis Pharmaceuticals
- RECRUITINGPHASE2NCT07305974A Phase IIa Clinical Study of RG002C0106 Injection in Subjects With Primary IgA NephropathyRigerna Therapeutics Co., Ltd.; Rigerna Therapeutics (Beijing) Co., Ltd.
- RECRUITINGPHASE4NCT07030894Nefecon and Ambrisentan in IgA NephropathyThe First Hospital of Jilin University
- RECRUITINGPHASE2NCT06989359Phase 2 Study of ADX-038 in Complement-Mediated Kidney DiseaseADARx Pharmaceuticals, Inc.
- RECRUITINGPHASE1NCT07054684Study of BHV-1400 in IgA NephropathyBiohaven Therapeutics Ltd.
- ENROLLING BY INVITATIONEARLY PHASE1NCT07135219A Study of Cizutamig in Patients With Immunoglobulin A NephropathyPeking University First Hospital